A detailed history of Legal & General Group PLC transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 92,379 shares of RNA stock, worth $3.91 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
92,379
Previous 76,049 21.47%
Holding current value
$3.91 Million
Previous $1.94 Million 94.48%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$22.73 - $40.85 $371,180 - $667,080
16,330 Added 21.47%
92,379 $3.77 Million
Q1 2024

May 14, 2024

BUY
$9.16 - $25.52 $157,680 - $439,301
17,214 Added 29.26%
76,049 $1.94 Million
Q4 2023

Feb 15, 2024

BUY
$4.87 - $9.37 $1,373 - $2,642
282 Added 0.48%
58,835 $532,000
Q3 2023

Nov 14, 2023

SELL
$6.3 - $11.35 $4,315 - $7,774
-685 Reduced 1.16%
58,553 $373,000
Q2 2023

Aug 14, 2023

BUY
$10.62 - $17.34 $316,231 - $516,333
29,777 Added 101.07%
59,238 $656,000
Q1 2023

May 15, 2023

BUY
$15.35 - $25.65 $111,916 - $187,014
7,291 Added 32.89%
29,461 $452,000
Q4 2022

Feb 14, 2023

BUY
$10.06 - $22.66 $54,555 - $122,885
5,423 Added 32.38%
22,170 $491,000
Q3 2022

Nov 14, 2022

SELL
$15.46 - $23.43 $41,649 - $63,120
-2,694 Reduced 13.86%
16,747 $274,000
Q2 2022

Aug 22, 2022

BUY
$11.18 - $20.5 $8,105 - $14,862
725 Added 3.87%
19,441 $282,000
Q1 2022

May 16, 2022

BUY
$14.2 - $23.78 $7,838 - $13,126
552 Added 3.04%
18,716 $345,000
Q3 2021

Nov 15, 2021

BUY
$18.16 - $25.21 $269,730 - $374,444
14,853 Added 448.6%
18,164 $448,000
Q2 2021

Aug 12, 2021

SELL
$19.62 - $29.26 $11,575 - $17,263
-590 Reduced 15.12%
3,311 $82,000
Q1 2021

May 17, 2021

BUY
$20.28 - $28.15 $25,532 - $35,440
1,259 Added 47.65%
3,901 $85,000
Q4 2020

Feb 12, 2021

BUY
$24.73 - $35.12 $19,066 - $27,077
771 Added 41.21%
2,642 $68,000
Q3 2020

Nov 13, 2020

BUY
$23.35 - $35.94 $43,687 - $67,243
1,871 New
1,871 $53,000

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $2.21B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.